Journal of the American Chemical Society · 2003 · 56 citations · 11 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryStructural BiologyDe Novo Drug DesignEnzyme InhibitionLead Compound DesignLead DiscoveryLigand BindingPotency OptimizationDiscoveryEarly Drug DiscoveryNon-nucleoside InhibitorsRational DesignStructure-based Lead DiscoveryStructure-guided Lead Discovery
We disclose herein the rapid discovery of the first highly potent (Ki = 7.7 nM) non-nucleoside adenosine deaminase (ADA) inhibitor based on the rational hybridization of two structurally distinct leads. Two micromolar inhibitors were discovered by a parallel rational design and random screening program, and individual crystal structures of bovine ADA in complexation with these inhibitors revealed several unknown binding sites and distinct binding modes. Using this information as the starting point, highly effective lead hybridization was achieved in only two structure-based drug design iterations. The conceptual approach illustrated by this example promises to be broadly useful in the search for new chemical entities and can contribute greatly to improve the overall efficiency and speed of drug discovery.
11
Hiroaki Mitsuya, Kent J. Weinhold, P A Furman et al. · Proceedings of the National Academy of Sciences · 1985 · 1.9K citations · Full text
MIF regulates innate immune responses through modulation of Toll-like receptor 4
Thierry Roger, John R. David, M. P. Glauser et al. · Nature · 2001 · 583 citations
Raymond W. Klecker, Jerry M. Collins, Robert Yarchoan et al. · Clinical Pharmacology & Therapeutics · 1987 · 381 citations